Antonia Lloyd-Lavery (A Lloyd-Lavery)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Monoclonal Antibody

Atopic Dermatitis

Top Venues

The British journal of dermatology

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Antonia Lloyd-Lavery
Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis. The British journal of dermatology (2023)
Antonia Lloyd-Lavery
Further evidence for the long-term safety of guselkumab. The British journal of dermatology (2023)
Karen E Harman, Jag Barha, Jo R Chalmers, John K G Dart, Isobel Davies, Patricia Ellis, Douglas J C Grindlay, Philip J Hampton, Sharleen Hill, Sharon Hockey, Antonia Lloyd-Lavery, Maggie McPhee, Ruth Murphy, Saaeha Rauz, Jane F Setterfield, Ingrid Thompson, Melanie Westmoreland, Christina Waistell
The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership. The British journal of dermatology (2023)
Yi-Ling Chen, Danuta Gutowska-Owsiak, Clare S Hardman, Melanie Westmoreland, Teena MacKenzie, Liliana Cifuentes, Dominic Waithe, Antonia Lloyd-Lavery, Allison Marquette, Marco Londei, Graham S Ogg
Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Science translational medicine 11 (515) (2020)
M K Shephard, Antonia Lloyd-Lavery
Resolution of severe oral mucosal changes related to vemurafenib therapy with intensive periodontal treatment. The British journal of dermatology 181 (3) (2019)
Antonia Lloyd-Lavery
Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis. The British journal of dermatology 179 (4) (2019)